Biologic therapies committee. What does it provide?

Objective: To assess the general healthcare impact of a Biological  Therapies Commitee (immune-mediated inflammatory diseases) through  prescription habits, pre-biological studies and immunization.

Method: A quasi-experimental study was conducted on all naïve patients  of legal age who started treatment with a biological agent for an immune- mediated inflammatory disease the year before and the year after the  creation of the Biological Therapies Committee.

Results: A total of 31 patients treated in 2016 and 40 patients treated in 2018 were included.

Implementation of an anti-flu vaccination campaign in a hospital pharmacy service.

Objective: To determine the impact of the implementation of an  influenza vaccination campaign in a hospital pharmacy service on  patients who are starting or receiving treatment with biological  therapies.

Method: A 15-month quasi-experimental study of patients starting or receiving treatment with biological therapies. Between October and  December 2016 and October and December 2017, we compared  influenza vaccination rates, the incidence of influenza in the study  population, the direct impact of the vaccination campaign on the  patient, the effect of the campaign on vaccination rates, and the results  of the satisfaction survey.

[Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin's lymphoma].

Clinical Case: A 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were  administered.